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Mutated constitutively activated forms of the BRAF kinase have been associated with 
various cancers, such as melanoma and leukemia.  One such common BRAF mutant, 
BRAFV600E is found in about 50% of melanomas.  BRAF is part of the MAPK signaling 
cascade that contains the downstream target MEK1/2, which phosphorylates ERK1/2 and 
subsequently increases cell proliferation. While the majority of the therapeutic inhibitors of 
the MAPK pathway have been designed to target BRAF, some have also targeted MEK1/2 as 
well as other kinases within the pathway such as ERK1/2. Recently, MEK1 has been 
observed to interact with copper (Cu).  This element and copper transporter 1 (CTR1) were 
found to be important for kinase activity and when absent, decreased the ability of 
BRAFV600E to signal and mediate tumorigenesis.  In this study, work was done to further 
characterize the MEK1-Cu interaction through crystallography, and carried out associated 
biochemical and enzymatic studies in order to characterize the functional consequence of the 
interaction and its effects on downstream ERK phosphorylation.  A crystal structure of a 
MEK1-Cu complex was obtained revealing a Cu binding site to a regulatory site of the 
kinase that would be predicted to inhibit kinase activity.  This structural observation is 
supported by functional studies with bacterially produced recombinant homogeneously 
purified MEK1 demonstrating that Cu inhibits MEK1 kinase activity in vitro.  Interestingly, 
crudely purified MEK1 did show Cu-mediated MEK1 activation suggesting another mode of 
Cu-mediated MEK1 activation that is yet to be characterized. These results suggest that 
MEK1 is a metal-sensitive enzyme and that targeting these metals may be exploited to inhibit 
MAPK signaling for therapy. 
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Introduction 
Importance & Significance 
Cancer is a class of diseases that cause unregulated division of abnormal cells 
within different body systems or organs.  It is one of the most potent classes of diseases, 
since an overall cure has yet to be discovered.  In response to this, many labs have 
dedicated their research to understanding the molecular underpinnings of cancer in order 
to develop effective therapies.  Cancer can result in the mutational activation of cellular 
lines of communication that drive cellular proliferation.  Since cancers are caused by 
different underlying abnormalities, cellular pathways and macromolecules must be 
studied in order to develop effective targeted therapies. Melanoma targets the skin and is 
mostly caused by over exposure to natural and artificial ultraviolet rays, but has also been 
tied to a combination of genetics and other environmental factors.1  Since melanoma 
incidence is steadily rising, with mortality rates of 1 in 8 people in the last decade, it is 
imperative to find effective treatments for the projected 144,000 people who will be 
diagnosed in 2016 alone.2  This cancer exploits normal cellular signal transduction 
pathways to promote uncontrolled cell division, a hallmark of cancer. In a healthy 
individual, different enzymes and proteins communicate within signal transduction 
pathways to cause specific biological activities, such as cell growth and division. In 
normal signal transduction, the initial signal is received from the extracellular 
environment, and read by a membrane-bound receptor protein, which then elicits an 
initial intracellular event. Signaling then proceeds within the cell to modulate metabolism 
and gene expression programs to drive different biological pathways. However, errors or 
alterations of these processes cause diseases such as cancer and metabolic disorders.   
 
Purpose & Hypothesis 
This project is based on a report demonstrating that copper (Cu) is required for 
BRAF signaling and tumorigenesis through direct stimulation of MEK1 kinase activity.3 
The focus of this project is to on understand the molecular basis for how Cu binds and 
stimulates MEK1 kinase activity towards its downstream substrates (ERK1/2). There are 
two mechanisms that we hypothesized to be the most plausible.  In one mechanism, 
copper could allosterically activate MEK1 for more efficient ERK1/2 phosphorylation.  
In a second mechanism, Cu could strengthen the interaction between MEK1 and ERK1/2, 
thus leading to enhanced ERK1/2 phosphorylation.  This is of importance to study in 
order to find new methods to inhibit the kinases in this pathway responsible for cell 
proliferation and cancer. Since MEK1/2 are the first mammalian kinases to be found to 
interact with a transition metal, this study is also of general biological importance.  
Furthermore, the oxidation state of the Cu species interacting with MEK1 is unclear.  
While Cu+ is rare and unstable compared to Cu2+, it is possible that within the 
phosphorylation process there is a fleeting moment where Cu+ is stabilized and oxidized 
to Cu2+ by the reducing environment within the cell influencing MEK1’s ability to 
phosphorylate ERK2.  While more difficult to determine, more information regarding the 
oxidation state of Cu on this can be elucidated through this study. 
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Background 
MAPK Pathway 
 Kinases are enzymes that are responsible for phosphorylating other proteins to 
signal different actions.  Since kinases all have the role of phosphorylation, they contain 
conserved motifs that mediate conserved enzymatic activities.  One such conserved motif 
is the activation segment (loop), labeled in Figure 1a, which typically lies between a 
conserved Asp-Phe-Gly and Ala-Pro-Glu sequences and is typically the site of regulatory 
phosphorylation.4 A Gly-rich loop is another conserved region in the amino terminal end 
of the kinase domain.  This is a flexible loop with a consensus motif of Gly-X-Gly-X-X-
Gly that locks the ATP phosphates into the catalytic site.4 The BRAFV600E mutation 
occurs in the activation segment and causes a 500-fold increase in activation of the 
downstream MEK1 kinase.  The V600E mutation in BRAF mimics activation loop 
phosphorylation of the wild-type BRAF kinase, thus rendering the kinase constitutively 
active for MEK1 phosphorylation.   
 The MAPK pathway is organized into a three-tiered kinase signaling network. 
The pathway of interest begins with Epidermal Growth Factor (EGF), which binds to its 
receptor (EGFR) on the cell membrane and leads to regulation of transcription factors 
within the nucleus.  The canonical MAPK pathway is being studied, that includes the 
enzymes RAS, RAF (A, B and C isoforms) which corresponds to Tier 1 in Figure 2, 
MEK (MAP2K1 and MAP2K2 isoforms) which corresponds to Tier 2 in figure 2, and 
ERK (MAPK1 and MAPK3 isoforms) which corresponds to Tier 3 in Figure 2.  
Specifically, active GTP-bound RAS binds to activate the serine threonine kinase RAF.  
The RAF kinase then phosphorylates and activates the kinases MEK1 and MEK2.  This 
study focused on the Tier 2 kinase in the cascade with dual specificity (MEK1) encoded 
by the MAP2K1 gene.  This protein is also responsible for acting as an integration point, 
in which different signals are attached to MEK1 to allow for different responses to 
activate cellular processes such as proliferation and differentiation.5 Within the MAP 
kinase signal transduction pathway, MEK1 is activated by many extra- and intra- cellular 
signals.  Upon activation, it then stimulates the enzymatic activity of MAP kinases for 
further phosphorylation and activation of other enzymes.  This type of phosphorylation is 
called a kinase cascade6, where a phosphorylation event activates a kinase and then that 
activated kinase phosphorylates another kinase and so on (Figure 2).  MEK1 then 
continues further downstream to the next kinase, and in mammals that is the 
extracellular-signal-regulated kinases (ERKs). 
 Extracellular-signal-regulated kinases (ERK) are protein kinase intracellular 
signaling molecules that are ubiquitously expressed.  They are activated by various 
stimuli, including growth factors, cytokines, and transforming agents.  Upon their 
activation, ERKs regulate meiosis, mitosis, and post-mitotic functions depending on the 
cell type.  ERK2, also referred to as MAPK1, has other roles than phosphorylation within 
the cell, as it also activates physiological responses through nuclear translocation.5  
Nuclear translocation is simply the process of proteins or other macromolecules being 
transported from the cytoplasm to the nucleus.  Due to translocation of Ser-Pro-Ser site, 
downstream acidic residues, and other elements through passive and active processes, 
ERK2 phosphorylates casein kinase 2 (CK2), which is responsible for regulating 
apoptosis.5  Due to the combination of its growth factor effects and CK2 interaction, 
ERK2 has become of particular interest for anti-cancer drug design.  For this reason, this 
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study focuses on the effects of MEK1 (Tier 2) on ERK2 (Tier 3) phosphorylation (Figure 
2) with relation to different additives. 
 While the MAPK pathway is normally tightly controlled, several cancers exploit 
this pathway via kinase mutations that result in constitutive, unregulated, activation of the 
pathway. Upstream activation of the Receptor Tyrosine Kinases (RTKs), like EGFR, and 
mutations in RAS genes can cause cancer.  Therefore, many of the kinases within this 
pathway have been studied as potential targets for inhibition for therapy.  For example, 
~50% of all melanoma patients have been identified to have a V600E mutated B-RAF 
resulting in unregulated B-RAF activation, uncontrolled cell division, and tumor growth.7  
The reason these are such prevalent drug targets is because they are driver mutations in 
cancer and the cells depend on them for growth.  In order to effectively eliminate cancer 
in these patients, the MAPK pathway must be inhibited and resistance mechanisms, 
which often occur after therapy, must be avoided.5   
 
 
 
Figure 1. Structural viewpoints of MEK1’s active site bound to inhibitor PD318088.8 
 
Current State of MAPK Pathway Inhibition 
 There have been many studies reported focusing on the development of small 
molecule MAPK pathway inhibitors.  Many of these studies have focused on targeting 
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RAF and MEK for inhibition.  These studies have exploited information about the X-ray 
crystal structures of B-RAF and MEK (Figure 1) and have led to the development of 
several potent inhibitors that have entered clinical trials and are currently used for 
therapy.  Current BRAF inhibitors include Vemurafenib and Dabrafenib, which disrupt 
the BRAF-MEK interaction and cause apoptosis within melanoma cell lines.3 Although 
many patients show a positive initial response to these inhibitors, all patients develop 
drug resistance causing cancer relapse.  Additional inhibitors have been designed to 
combat the relapse that occurs through paradoxical activation of BRAF4, but more 
effective approaches are being researched to overcome this feedback loop.  While few, 
MEK inhibitors include Trametinib, Cobimetnib, and MEK162, which inhibits 
anchorage-independent growth of Ki-Ras by blocking ERK and rapamycin-p70 
pathways.4  Due to the high efficiency of the MAPK cascade, most MEK1 inhibitors are 
used in combination with BRAF treatments in order to inhibit the entire pathway.  While 
these MEK1 inhibitors are effective in combination with BRAF treatments, independent 
therapeutic strategies are needed.  MEK1 is also involved in other cancers, such as 
ovarian and breast cancers, thus it needs to be further studied in order to understand the 
sites to target for new inhibitors.  
 
 
 
Figure 2. The canonical MAPK pathway.  The Pi symbols shown on MEK1/2 and ERK1/2 symbolize 
phosphorylation at those residues (S or T, Y respectively).5  The interactions for this study focus on Tier 2 
(MEK1) and its interaction with Cu to phosphorylate Tier 3 (ERK2). 
 
Studies Implicating Copper in MEK1 Activation 
A recent study by Dr. Brady and colleagues discovered that an increase in copper 
(Cu) enhances the ability of MEK1 to phosphorylate ERK1/2.3 The studies included 
testing the role of the Cu transporter 1 (Ctr1) in this process and demonstrated that 
decreasing the Cu concentration in mouse cells decreases the phosphorylation levels of 
the ERK1/2 kinases.  The authors also conducted a number of studies on tumorigenesis 
and demonstrated that decreasing the level of Ctr1 or mutating regions of MEK1 that 
mediate Cu-activation of MEK1 activity inhibits tumor growth.  To show the dependence 
of Cu’s role within cells, the number of tumors was used to determine the effects of Cu 
with the Ctr1 gene present and absent.  By removing Ctr1 with Cu present, the number of 
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visual tumors, shown as white arrows on Figure 3a, decreased within an excised lung 
(Figure 3b).3  To confirm that not only tumors, but tumor cells were being affected by the 
absence of Ctr1, tumor cell percentages were studied through the quantification of a 
histochemical stain.  Figure 3c and 3d shows a histochemical staining image. The darker 
pink spots correlates with abnormal/tumor lung tissue. Figure 3c shows a higher 
percentages of abnormal/tumor lung tissue than Figure 3d.3 MEK1’s ability to 
phosphorylate ERK (p-ERK) with and without Ctr1 was also tested within the tumors.  
The amount of p-ERK signal (red histochemical staining on Figure 3e) was greatly 
reduced (Figure 3f) to a point of cell “moribundity”.3 Conversely, activating the MAPK 
pathway in a Cu independent (no additive) fashion stimulated tumor growth (Figure 3).  
All of these findings combined, highlight the importance of Cu’s regulation of MEK1 
activity for driving the MAPK pathway and point to the inhibition of Cu-mediated MEK1 
activation as a potential novel strategy to inhibit MAPK signaling in melanoma patients 
with the BRAFV600E mutation.3 
 
 
 
Figure 3. Histochemical tissue samples with statistical analyses of tumorous cancer cells present with 
respect to presence and absence of Ctr1 and pERK1/2.3 
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 Given the knowledge of the MAPK pathway1-8, evidence displaying activation 
with Cu3 (Figure 3), and understanding the limitations of the current MEK inhibitors, it 
becomes evident that more studies are needed.  This study looks to characterize the 
interaction between MEK1-Cu by determining the MEK1 residues and Cu oxidation state 
involved through crystallography.  After solving the structure and determining the 
residues, mutagenesis can be combined with in vitro assays to qualitatively and 
quantitatively determine the influence of Cu on MEK1.  These assays will characterize 
the MEK1-Cu complex and gain better insight on the Cu-interaction residues’ roles 
within MEK1 (Tier 2) for phosphorylating ERK2 (Tier 3) when Cu (additive) is bound 
and unbound.   
 
Materials and Methods 
General Consideration 
MaxQ™ 8000 Incubated Stackable Shakers (ThermoFisher Scientific): All of the protein 
growths for purification were conducted within the MaxQ™ 8000 Incubated Stackable 
Shakers (ThermoFisher Scientific).  These stackable shakers have the durability to run at 
a top speed of 400 rpm overnight, contain a HEPA filter that ensures pure air inside the 
chamber and reduces cross contamination between protein growths, and a slide out 
platform that provides 100% sample access at all times. 
 
ÄKTA pure 25 L and UNICORN software (GE Healthcare Life Sciences):  All 
Sepharose and Superdex columns for protein purification were run on the ÄKTA pure 25 
L (GE Healthcare Life Sciences) for Fast Protein Liquid Chromatography (FPLC).  
These instruments are used to further enhance affinity column protein purifications and 
separation from undesired products through a broad selection of hardware options (ie. 
valves, tubing, and columns). The UNICORN control software is also used to determine 
the protein elution and provides various readings, such as UV and mAmps, to further 
optimize protein purification techniques for each unique protein.   
 
Beamline 24ID-C (Advanced Photon Source synchrotron):  All crystals were shot at the 
Advanced Photon Source (APS) synchrotron through remote access for crystallographic 
studies.   The APS synchotron is optimized to address cases in macromolecular 
crystallography by providing extremely stable and intense X-ray beams with beam sizes 
ranging from 5 to 70 microns. The 24ID-C beamline was solely utilized due to it being a 
variable energy beamline, which allowed for the energy of the beam to be tuned 
appropriately to detect the most electrons present for a specific element.  This created an 
anomalous signal density that was present when solving the structures.  This anomalous 
density was only present when the element of interest was bound to the structure.  No 
anomalous signal would be detected unless the element of interest was present in the 
structure or crystal. 
 
Invitrogen XCell II Blot Module and Novex XCell SureLock Mini-Cell (ThermoFisher 
Scientific):  All SDS-Page gels transfers to PVDF membrane were conducted by an 
Invitrogen XCell II Blot Module in a Novex XCell SureLock Mini-Cell (ThermoFisher 
Scientific).  This allows for easy transfer of proteins or nucleic acids from gels to 
membranes. It fits within the XCell SureLock Mini-Cell and requires less than 200 mL of 
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transfer buffer for Western, Southern, and northern transfers. Tough platinized titanium 
and stainless steel electrodes help create a uniform electrical field without clamps or 
hinged gel holders that are known to alter results. 
 
EnVision Multilabel Plate Reader (PerkinElmer):  All Enzyme-Linked ImmunoSorbent 
Assays were processed and read by the EnVision Multilabel Plate Reader (PerkinElmer).  
EnVision’s wide range of filters and optical mirror modules cover the UV/Vis 
wavelength range, so direct measurement of DNA and protein is possible. This can also 
achieve high performance detection of all ELISA assays and immunoassays using 
different labels. 
 
ImageJ Western Blot Quantification Software: Quantification of all Western bands were 
completed using the ImageJ software.  This was completed by selecting an area by 
drawing a rectangle around the band.  The same rectangular area was utilized for all the 
bands in each gel for each subset, ie. with or without DTT. A quantification number is 
displayed under or below each associated band. 
 
Plasmids and Constructs 
 Multiple recombinant protein constructs were prepared for the experiments 
conducted in this study.  Rabbit cDNA encoding a library of MEK1 residues from 1 – 
393 was utilized for insertion into a PET28A vector with a N-terminal 6-Histidine-tag 
and cleavable TEV site (Met-Glu-Asn-Leu-Tyr-Phe-Gln-Gly-Ser) for tag removal.  The 
PET28A plasmid is used as the vector to make the MEK1 protein and insert expressible 
in E. coli through the lac operon.  PCR reactions were setup with the MEK cDNA library 
(insert) and the PET28A plasmid (vector), to excise the insert and create an opening in 
the vector for the insert.  Similarly, MEK1 with an N-terminal GST-tag was inserted into 
a pGex-3t vector.  These PCR reactions mixes occurred in two separate tubes and 
included 43 μL insert or 42 μL template (vector only), 1 μL restriction enzyme #1, 1 μL 
restriction enzyme #2, and 10 μL 10x Cut Smart buffer.  To the reaction with vector 
alone, 1 μL of Calf Intestinal Phosphatase (CIP) was added to protect the cut ends of the 
vector from auto-ligating with itself.  After the PCR reactions are complete, the 
insert:vector ratios of 0:2, 0.75:2, 1:2, and 1.25:2 were mixed and diluted up to 10 
μL with nanopure water.  A volume of 10 μL ligation mix was added to ligate the 
mixtures and allowed to incubate for 1 hour at 25°C on the bench.  PCR on the insert 
only, then combine the plasmid and insert to ligate with the ligase.  After PCR, 1 μL 
Dpn1was added to remove any methylated DNA nucleotide sites and incubated 
overnight.  These ligation mixtures were added as 10 μL volumes into XL1Blue or DH5α 
cells to transform for DNA expression.  After 20 minutes on ice, the samples were heat 
shocked at 42°C for 50 seconds and 250 μL of Lysogeny Broth (LB) was added to the 
cells.  The cells shook at 37°C for 1 hour and were then plated on antibiotic agar plates.  
These were incubated overnight at 37°C for cell colony growth.  Kanamycin at 1 mM 
was used for all 6-His-tagged constructs and 1 mM Ampicillin was used for GST-tagged 
constructs. 
If colonies grew, they were mini-prepped by selecting colonies and placing each 
in a culture tube with 5 mL LB and 5 μL of antibiotic.  These were shaken overnight at 
37°C for growth.  Next, the culture tubes were spun down for 15 minutes at 4200 rpm.  
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The solution was decanted, with the remaining pellet dissolved in 250 μL P1 
resuspension buffer and transferred to an Eppendorf tube.  The cells were then lysed with 
250 μL P2 lysis buffer and inverted a few times to mix.  Finally, 350 μL N3 neutralizing 
buffer was added to neutralize the cell lysis.  The samples were then spun down at 13,300 
rpm at 25°C for 10 minutes and the supernatant was decanted from the pelleted 
precipitate and applied to a spin column with a DNA binding membrane over a vacuum 
manifold. The supernatant was vacuumed off and a wash with 500 μL phosphate buffer 
(PB) to allow efficient binding of the DNA to the spin column.  A final wash was carried 
out with 750 μL PE wash buffer to remove other unwanted components, while keeping 
DNA bound to the spin column.  The spin column was spun for 1 minute at 25°C at 
13,300 rpm to remove excess liquid in the spin column and another spin cycle with 30 μL 
of nanopure water was completed to elute the DNA off the spin column.  These samples 
were then sequenced to confirm successful insertion by adding 3 μL of plasmid, 3 μL of 
forward/reverse primer, and 3 μL of nanopure water. 
The following is a list of all the constructs produced for this study: 
 6-His-TEV constructs 
 MEK Full Length (FL) 
o Wild Type (wt) 
o H188A 
o H188F 
o C207S 
o H188A/C207S (double mutant) 
 MEK FL S218D, S222D (DD) 
o wt 
o H188A 
o C207S 
o Double mutant 
 Glutathione-S-Transferase (GST) constructs 
 MEK1 FL 
o wt 
o H188A 
o C207S 
o C121S 
o Double mutant 
 MEK1 FL DD 
o wt 
o H188A 
o C207S 
 ERK2 FL 
o K54R 
 Crystal constructs 
 MEK1 45 – 393 with a GSGSGS or SVQSDI linker region 6-His-TEV 
 MEK1 62 – 393 with SVQSDI linker 6-His-TEV  
. 
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Cloning and Mutagenesis 
Cloning and mutagenesis of all constructs were carried out similarly with 
differences being in the primer concentrations and PCR reaction programs.  The primers 
for site-specific mutagenesis were designed by mutating the nucleotide sequence of target 
codon for desired amino acid, with 21 nucleotide (equaling 7 amino acids) overhangs on 
5’ and 3’ sides.  The PCR reaction mixtures for mutagenesis contained 23 μL nanopure 
water, 1 μL of ~75 μg/μL template (plasmid), 0.5 μL 1:17 forward primer, 0.5 μL 1:17 
reverse primer, 25 μL Master Mix; while cloning mixtures contained 23 μL nanopure 
water, 1 μL template (plasmid), 0.5 μL 1:100 forward primer, 0.5 μL 1:100 reverse 
primer, 25 μL Master Mix.  After PCR, 1 μL Dpn1 was added to remove any methylated 
DNA nucleotide sites and incubated overnight.  These were then transformed into DNA 
expression cell lines, ie. DH5α or BL21 (Gold) cells, through the addition of 10 μL PCR 
reaction to cells and placing on ice for 20 minutes.  The samples were then heat shocked 
at 42°C for 50 seconds and 250 μL LB was added to cells and incubated for 1 hour at 
37°C while shaking.  These were then plated on antibiotic agar plates and incubated 
overnight at 37°C.  DNA was extracted through the mini-prep protocol explained 
previously and sequenced to confirm protein sequence and mutations made. 
 
Protein Expression and Purification 
 The DNA-sequenced constructs were transformed into protein expressing cell 
lines, ie. DE3 or Rosetta cells, for induction and expression in E. coli.  A volume of 1 μL 
of plasmids were transfected into cells and incubated on ice for 20 minutes.  The cells 
were then heat shocked at 42oC for 50 seconds and 250 μL LB was added.  These 
samples were then incubated for 1 hour at 37°C shaking and then added to a 100 mL LB 
solution with 100 μL of 1 mM antibiotic.  The inoculated LB solutions were shaken 
overnight at 37oC.  A volume of 8 mL of the overnight growth and 1 mL of 50 mg/mL 
KAN for His constructs, or 100 mg/mL AMP, for GST constructs, were added to 1 L LB 
or TB. 
His-tagged MEK1 proteins were expressed in Rosetta bacterial expression cells in 
E. coli at 37°C in MaxQ™ 8000 Incubated Stackable Shakers (ThermoFisher Scientific).  
These were induced with 1 mM IPTG after an OD of 600 was reached and left shaking 
overnight at 18°C.  The next day, they growth were spun down and lysed through 
sonication in lysis buffer 25 mM Tris pH 8.0, 250 mM NaCl, 1 mM PMSF, and ~50 mg 
DNase. The lysate was then spun down at 18,000 rpm for 30 minutes, and the supernatant 
was added to 8 mL of equilibrated nickel (Ni-NTA) affinity resin.  The supernatant was 
left to incubate and rotate at 4°C for 1 hr. The affinity column was then washed with 25 
mM Tris pH 8.0, 250 mM NaCl, and 20 mM Imidazole.  The MEK1-His-tag protein was 
eluted with 25 mM Tris pH 8.0, 250 mM NaCl, and 300 mM Imidazole.  TEV was added 
to the protein to cleave between the N-terminus 6 His-tag and the beginning of the MEK1 
sequence.  This was occurred during overnight dialysis into a low salt buffer (25 mM Tris 
pH 8.0, 20 mM NaCl, and 5 mM BME) to run on a 5 mL Q-Sepharose anion exchange 
column.  The one exception to this was the MEK 45 – 393 6-His TEV w/ SVQSDI or 
GSGSGS linker crystallization construct that was run over a 5 mL SP-Sepharose cation 
exchange column.  The column with the 6-His-tag cleaved protein was run over a 
gradient of 20 mM – 1 M NaCl with 25 mM Tris pH 8.0 and 5 mM BME present.  The 
peak fractions containing protein were run on an SDS-PAGE acrylamide gel to identify 
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peak protein fractions at the correct molecular weight (kDa).  These fractions were 
combined and concentrated to ~12 mL to run over another Ni-NTA affinity resin column 
for a reverse Ni2+ to remove any remaining uncleaved His-tagged protein.  This column 
was equilibrated, washed, and eluted with a 25 mM Tris pH 8.0, 250 mM NaCl, and 20 
mM Imidazole buffer.  The protein was then concentrated to run on a Superdex S200 gel 
filtration column in a final buffer of 25 mM Tris pH 8.0, 250 mM NaCl, 5 mM BME, and 
5% glycerol.  Protein was flash frozen in liquid nitrogen and stored in -80°C freezer for 
future use.  
GST-tagged MEK1 and ERK2 K54R proteins were expressed in Rosetta bacterial 
expression cells for E. coli at 37°C in MaxQ™ 8000 Incubated Stackable Shakers 
(ThermoFisher Scientific).  These were induced with 1 mM IPTG after an OD of 600 was 
reached and left shaking overnight at 18°C.  The next day, they growth were spun down 
and lysed through sonication in lysis buffer 25 mM Tris pH 7.5, 250 mM NaCl, 1 mM 
PMSF, and ~50 mg DNase. The lysate was then spun down at 18,000 rpm for 30 minutes, 
and the supernatant was added to 8 mL of equilibrated Glutathione affinity resin.  The 
supernatant was left to incubate and rotate at 4 °C for 1 hr. The affinity column was then 
washed with 25 mM Tris pH 7.5, 500 mM NaCl, and 5 mM BME.  The GST-tagged 
protein was eluted with 25 mM Tris pH 7.5, 500 mM NaCl, and 20 mM glutathione 
buffer that was re-pH to 7.5 after addition of L-reduced Glutathione.  The protein was 
dialyzed overnight into a low salt buffer (25 mM Tris pH 7.5, 20 mM NaCl, and 5 mM 
BME).  After dialysis, the GST-tagged protein was concentrated and run on a Superdex 
S200 gel filtration column in a final buffer of 25 mM Tris pH 7.5, 250 mM NaCl, 5 mM 
BME, and 5% glycerol. If additional purification was needed, the dialyzed protein could 
first be run on a Q-Sepharose anion exchange column over a 20 mM – 1 M NaCl 
gradient. Lastly, protein was flash frozen in liquid nitrogen and stored in -80°C freezer 
for future use.  
 
Crystallization 
MEK1 45 – 393 w/ SVQSDI linker at 10 mg/mL was mixed with 2 mM 
Adenylyl-imidodiphosphate (AMP-PNP) w/ and w/o 2 mM Mg2+.  Trays were setup with 
the crystal condition of varying polyethylene glycol (PEG) 3350 concentrations (8 - 
24%), 4% Glycerol, 200 mM NH4F, 10 mM dithiothereitol (DTT) (99% pure, cat 
#BP172-25, Fisher BioReagents) using the hanging-drop vapor diffusion method at 4°C.  
Cu was soaked in by soaking in solution without DTT present and by doing long, short, 
and back soaks in various concentrations of Cu2+.  Cryo-conditions were obtained by 
taking the mother liquor and increasing the glycerol to 20%.  Crystals obtained were used 
for X-ray diffraction data collection at the Advanced Photon Source synchrotron 
(beamline 24ID-C).  This tunable beamline was used to shoot at an anomalous edge of 
~9.1 keV in order to detect anomalous density corresponding to the position of Cu in the 
structure.  The crystals of MEK1 45 – 393 with SVQSDI linker with and without Cu 
were processed using HKL-2000. 
  All of the crystal structures were determined by molecular replacement in 
PHENIX using Phaser.  The apo MEK1 45 – 393 with SVQSDI linker structure was 
determined using PDB 3SLS9 as a search model in Phaser, which was then used for the 
MEK1 45 – 393 Cu-bound structures as a search model.  Model building and refinement 
were performed with Coot and PHENIX.  AMP-PNP was built into the structure by 
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downloading its PDB file and building it in through PHENIX and then running the 
structure through PHENIX refine.  Table 1 statistics were produced using the PHENIX 
validation tools.  Cu binding coordinates were drawn in by Coot based on the displayed 
density within the structure.  This electron density was confirmed to not be Mg2+ due to 
the absence of Mg2+ in these crystal conditions and the beamline’s tuned wavelength 
detecting solely Cu density.  The Cu-coordination sites of H188, C207, and D208, match 
residues that were previously tested through mutational studies in vivo.3 
 
In vitro studies 
Western Immunoblotting 
Protein samples were prepared to a total volume of 26 μL with concentrations of 
200 nM MEK1 FL, 25 nM MEK1 DD FL, or 1 μM MEK1 FL wt GST (crude); 4.5 µM 
ERK2-GST K54R; 5 – 20 μM Cu(I), Cu2+, or Ag+; and 100 μM ATP.  MEK1 and ERK2 
were diluted with kinase buffer (50 mM HEPES pH 7.0, 50 mM NaCl, and w/ & w/o 2 
mM DTT), while ATP was diluted with ATP dilution buffer (10 mM MgCl2, 50 mM 
HEPES pH 7.0, and 200 mM NaCl).  The reactions were shaken for 5 minutes and then 
left standing on the bench for 35 minutes at 25°C.  The reactions were quenched with 5x 
loading dye and boiled at 95°C for 5 minutes.  The samples were then run and separated 
on 12.5% sodium dodecyl sulfate polyacrylamide gels.  Proteins were transferred onto a 
nitrocellulose membrane (cat #170−4152, Bio-Rad) using a Trans-blot Turbo transfer 
system (Bio-Rad).  Nitrocellulose membranes were blocked in 2.5% Nonfat milk in TBS 
containing 1% Tween-20 (TBST) for 45 minutes at 25°C.  Incubation with primary 
antibody of phospho- Erk1/2 (T202/Y204) rabbit antibody (for cell signaling) at 1:1000 
dilution was performed overnight at 4°C in 2.5% Nonfat milk in TBST.  Membrane was 
washed four times (5 minutes each time) with TBST and followed by a 1 hour incubation 
with Alexa Fluor-labeled secondary antibody (goat-anti rabbit IgG (H+L)-HRP 
conjugate, cat #170-66515, Bio-Rad)) at a 1:5000 dilution in 2.5% Nonfat milk in TBST. 
Immunocomplexes were visualized after secondary antibody by washing the membrane 
four times (5 minutes each time) with TBST and developing with 5 mL of Pierce 
SuperSignal ECL solutions 1 and 2 together for 5 minutes.  The excess ECL was shaken 
off the nitrocellulose membrane and was then wrapped in plastic wrap to be placed in a 
autoradiography development cassette (FBXC 810, FisherBiotech) with BIOMAX MR 
chemiluminescent film within a photography dark room.  The film was developed with a 
film development machine. 
 
Enzyme-Linked IimmunoSorbent Assay (ELISA) 
 Protein samples were prepared at concentrations of 200 nM MEK1 FL or 25 nM 
MEK1 DD FL; 2.4 μg/μL ERK-GST K54R; 5 – 20 μM Cu(I), Cu2+, or Ag+; and 100 μM 
ATP.  MEK1 and ERK2 were diluted with kinase buffer (50 mM HEPES pH 7.0, 50 mM 
NaCl, and w/ & w/o 2 mM DTT), while ATP was diluted with ATP dilution buffer (10 
mM MgCl2, 50 mM HEPES pH 7.0, and 200 mM NaCl).  All volumes stated should be 
interpreted as volume per well.  A glutathione-coated 96-well plate (Pierce, cat#15240) 
was initially washed with 200 μL TBST to remove impurities and equilibrate the wells 
for 15 minutes. TBST wash was decanted and 100 μL of ERK2-GST K54R as added to 
each well with a multi-channel pipette.  The mixture was sealed and shaken for 1 hour at 
25°C. ERK-GST K54R was decanted and was mixed with 200 μL of 1X TBST for 15 
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minutes.  In a plastic 96 well tray, 100 μL of protein (untagged MEK) was aliquoted into 
each well and mixed with 1 μL additional additives (Cu, Ag, etc.) to allow thorough 
mixing and even incubation times.  From the aliquoted protein-additive mixes, 50 μL was 
added to the well and then 50 μL of 200 μM ATP was added to the glutathione 
plate.  The mixture was sealed and shaken for 5 minutes, then incubated at 25°C for 40 
minutes.  The protein-reaction mixture was decanted and 200 μL of 1X TBST was added 
to the wash and shaken for 15 minutes.  The primary antibody of phospho-Erk1/2 
(T202/Y204) rabbit antibody (for cell signaling) (cat #9101, Cell Signaling Technology) 
was diluted to 1:5000 into a dilution solution of 0.25% Bovine Serum Albumin (BSA) in 
1X TBST.  100 μL of primary antibody was added and shaken for 1 hour.  The primary 
antibody solution was decanted and washed twice by adding 200 μL of 1X TBST and 
shaken for 15 minutes twice.  After both washes, 100 μL of Alexa Fluor-labeled 
secondary antibody (goat-anti rabbit IgG (H+L)-HRP conjugate, cat #170-66515, Bio-
Rad) was added at a 1:5000 dilution in 0.25% BSA in 1X TBST solution and shaken for 
1 hour.  The secondary antibody solution was decanted and washed three times with 200 
μL of 1X TBST for 10 minutes each time.  After decanting washes, 5 mL of each 
SuperSignal ELISA Pico Chemiluminescent Substrate (Pierce #37069) solutions were 
mixed and add 100 μL of the mixture was added to the plate.  The plate was read on a 
PerkinElmer EnVision. Each value was repeated in duplicate or triplicate and averaged.  
The error bars are the calculated standard errors for each triplicate.   
 
Mass Spectrometry 
An acrylamide gel electrophoresis was run with the samples of interest.  The gel 
was handled with gloves on to prevent potential contaminants and followed the same 
procedure for staining and developing the protein bands as a normal gel with the excess 
Coomasie stain was removed by soaking in destain solution of 20% methanol, 10% 
glacial acetic acid, and 70% nanopore water.  These were then sent for LC-MS/MS for 
the bands of interest and the control band for the comparison with other bands. The bands 
of interest were cut out, digested with trypsin, and the digests were analyzed by LC-
MS/MS on a Q-Exactive Plus mass spectrometer. The mass spec data were searched 
against the combined UniProt E. coli/Sf9 database plus the recombinant protein sequence 
you have provided using the MaxQuant 1.5.2.8 program. False discovery rates for protein 
and peptide identifications are set at 1%.  This showed all of the identified proteins. 
Common contaminants (e.g. keratins) were removed, and proteins were required to have 
a minimum of 2 nonredundant (razor+unique) peptides. Different Intensity levels and 
MS/MS count columns were recorded to see which proteins were more abundant in each 
sample. This produced reports for the protein of interest and provided a summary of the 
analysis. 
 
Results and Discussion 
Crystal structure of the MEK1-Cu complex and implications for Cu regulation of MEK1 
To understand the molecular basis for the interaction between MEK1 and Cu, a 
crystal structure of MEK1 with and without Cu bound was determined.  For 
crystallographic studies of MEK1 without Cu, MEK1 45 – 393 His TEV with a SVQSDI 
or GSGSGS linker was utilized.  The 6-residue linkers replaced residues 264 – 307, 
which included a flexible loop that makes MEK1 difficult to crystalize.  The condition 
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that produced the highest resolution crystals contained 18% PEG 3350, 4% glycerol, 10 
mM DTT, 200 mM NH4F, and 2 mM AMP-PNP with and without Mg
2+ (Figure 4).  
After crystals were formed, soaks were conducted to remove DTT from the condition and 
soak in metals for efficient metal binding.  For the apo MEK1 45 – 393 crystals, the 
space group was P1 21 2 with 2 MEK1 molecules in the asymmetric unit and the 3SLS 
structure was a search model for molecular replacement.  The phased molecular 
replacement structure produced a data set of 2.3 Å resolution with solid geometry and 
refinement statistics (Table 1).  The search model (3SLS) and solved apo-structure were 
consistent with each other.  Both structures had different space groups of P21 and P1 21 2 
and the solved apo-MEK1 structure had 2 MEK1 subunits within the asymmetric unit 
(Figure 5a). The observed MEK1 dimer in the asymmetric unit appears to be an artifact 
of crystal packing due to there being no residue contacts for MEK1 dimerization to occur.  
The active state of kinases with an Asp-Phe-Gly (DFG) motif is determined by either the 
position of the entire loop being flipped in (active)10 or out (inactive)10, or the Asp or Phe 
positions within the active site10.  The overlaid structures (Figure 5b, 5c) show 
similarities in their active sites, with both DFG loops in the DFG-out conformation.  The 
solved apo-MEK1 45 – 393 structure’s Asp was flipped out and the Phe flipped in 
(Figure 5b, 5c), both of which signal an inactive conformation.  apo-MEK1 structure also 
did not contain Mg2+ and the ATP-binding site was occupied by ADP.  This is 
interesting, due to the apo-soaking condition containing MgCl2 and there being a 
prominent metal binding site that this study is probing.  While the lack of Mg2+ within the 
apo-structure differed from the search model, this could be beneficial for future metal 
binding soaks.  Due to Mg2+ absence, the potential issue of metal binding affinity for 
metal displacement, ie. Mg2+ for Cu2+, should not be an issue.  Another observation made 
was the density within the active site only contained space for 2 phosphate groups at the 
ATP binding site, thus ADP was modeled.  The ADP present in the structure may be one 
reason that an inactive conformation was observed. This would have been formed due to 
the used ligand, AMP-PNP, which is an ATP analogue with a non-hydrolyzable 
phosphate bond.  Since the kinase could simulate the ATP hydrolysis reaction with the 
AMP-PNP, it is possible that this locked the MEK1 F209 in an inactive or “off” 
conformation.  These absences are the most probable cause for the major difference 
between the 3SLS and the apo-MEK1’s Asp208 side chains positioning being 
significantly different.  In the apo-MEK1 structure, the Asp208 is flipped away from the 
search model’s Asp208 (Figure 5c).  This was likely caused by the α-helix proceeding the 
DFG-motif being closer to the active site due to the absence of Mg2+ and ATP’s third 
phosphate group.  These absences would allow for the α-helix slight flexibility within the 
active site confines to coil sooner and move closer to the DFG-motif.   
Upon solving the MEK1 structure without Cu, various attempts were made to 
introduce Cu to the protein for X-ray structure determination.  This was done by 
optimizing the condition to 20% PEG 3350, 4% glycerol, 200 mM NH4F, 2 mM AMP-
PNP.  Cu was introduced in a crystallographic setting through long, quick, or back soaks 
of Cu2+ at varying concentrations.  These crystals were used for X-ray data collection 
using a tunable beamline at an anomalous signal of ~9.1 keV in order to confirm and 
ensure the presence of Cu (Figure 6a).  Electron density differences were observed after 
analyzing the crystallography data with molecular replacement, PHENIX, and Coot, 
while utilizing the solved apo MEK1 45 – 393 structure as the search model for the 
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molecular replacement.  These differences included a large density cloud within the 
active site region (Figure 6b), which appears to be sharing density with the C207 side 
chain.    
 
 
Figure 4. MEK1 45 – 393 w/ SVQSDI linker apo crystals.  These are rectangular in shape and have a 
tendency of forming off of one another or plating back-to-back.  These apo-crystals are looped to remove 
DTT and used to soak in the metal of interest. 
 
The interaction sites were detected with the cysteine and histidine residues’ side chains, 
C207 and H188 respectively (Figure 6a).  The observation of Cu2+ at this site is not 
unusual, since this is also the site for Mg2+ and is directly upstream of the DFG-motif that 
binds to ATP.  Like Mg2+, we believed that Cu2+ had bound here due to it being a 
regulatory site.  The C207 residue is the closest ligand and appears to have the largest 
effect on the Cu based on the shared density displayed during refinement, while the H188 
side chain and D208 backbone help coordinate the Cu, and the F209 flips inward to cap 
the Cu in place.  Interaction distances are drawn (Figure 6c) in order to clarify the 
coordinating sites, due to only 1 site (C207) having a confirmed interaction with the Cu 
through density sharing.  The distances drawn from the Cu had values of 2.1 Å (H188) 
2.3 Å (C207), and 2.3 Å & 2.0 Å (D208’s backbone carbonyl and amide groups).  While 
F209 appears to cap the Cu, its bond distance (~10 Å) is too great to have any direct 
effect on the Cu.  Given all of the drawn distances (Figure 6c), these residues (H188, 
C207, and D208’s backbone) were determined to have van der Waals interaction forces 
responsible for coordinating the Cu ion.  Other studies that have studied Cu sites by 
crystallography11,12 have observed common trends of geometry patterns with Cu.  Given 
the distances for this structure, there were two potential geometry organizations for this 
Cu, disordered tetrahedral or square planar coordination.  The disordered tetrahedral 
geometry typically has drastically unsymmetrical distances for each bond length and is 
associated to Cu+.11,12  The MEK1-Cu structure’s H188 and C207 bond lengths, as noted 
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above, are approximately equivalent.  This equivalence or symmetry is a characteristic 
associated solely with the square planar conformation.12  The square planar conformation 
is associated to Cu2+ and generally observed for inactive state proteins.12  This helped to 
conclude that the Cu oxidation was Cu2+ with the solved MEK1-Cu structure and the 
inactive state was further confirmed by the DFG residues’ positions. To see how drastic 
of a conformational change the Cu2+ caused the apo structure was overlayed with the Cu 
bound structure (Figure 7).  The most notable difference is the change that D208 
undergoes, which shifts out of the way to allow the Cu2+ to “bind”.  Another large 
structural change is the H188 side chain flipping inward toward the Cu2+ to help 
coordinate it in place.  This residue (H188) has another notable feature of being part of 
the HRD domain.  The His-Arg-Asp (HRD) domain is a regulatory motif within the 
catalytic loop that helps regulate the kinase activity of MEK1 by properly positioning the 
DFG-Asp and αC-helix’s Lys-Glu contacts.13  While the HRD domain does not directly 
cause phosphorylation, it is an important regulatory site that when affected, drastically 
influences the activity level of MEK1.  Finally, C207 and F209 shift accordingly to 
enhance the interaction of the other residues with Cu. 
 
Table 1. Summary of MEK1 Crystallographic Statistics. 
Crystal 
MEK1 45 - 393 wt His-cut 
w/ SVQSDI (w/o Cu)* 
MEK1 45 - 393 wt His-cut 
w/ SVQSDI (w/ Cu)* 
Resolution range (Å)          50  - 2.4 (2.44  - 2.4)  50  - 2.3 (2.34  - 2.3) 
Space group                          P1 21 1  P1 21 1 
Unit cell  (a, b, c, α, β, γ) 46.581, 94.739, 72.793, 90, 
93.28, 90 
47.042, 95.027, 72.288, 90, 
94.2, 90 
Total reflections                            51133 88824 
Unique reflections                            22800 26017 
Redundancy                   2.2 (2.2) 3.3 (2.8) 
Completeness (%)                    92.71 (88.24) 90.94 (65.42) 
Mean I/σ(I)                       9.50 (4.71) 7.98 (2.70) 
Wilson B-factor                             24.43 28.65 
R-merge                      0.063 (0.142) 0.11 (0.752) 
R-work                   0.1957 (0.2151) 0.2528 (0.3473) 
R-free                  0.2495 (0.2781) 0.3020 (0.4153) 
Number of atoms                              4813 4552 
macromolecules                            4518 4552 
ligands                                  62  
 water                                 201 0 
Protein residues                               598 598 
RMS (bonds)                             0.004 0.003 
RMS (angles)                             0.81 0.82 
Ramachandran favored (%)                                98 98 
Ramachandran outliers (%)                                 0 0 
Clashscore                             6.29 5.86 
Average B-factor                             30.9 45.6 
macromolecules                             30.8 45.6 
ligands                                  31.9  
solvent                                  32.6  
*PHENIX refined statistics produced from solved MEK1 45 – 393 wt His cut w/ SVQSDI linker with and 
without Cu bound structures. 
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Figure 5. MEK1 45 – 393 w/ SVQSDI linker apo structures: (a) the crystal packed MEK1 dimer with ADP 
bound and absence of Mg2+, (b) vertical perspective of active site with search model 3SLS (green) and apo-
MEK1 structure (pink) overlaid displaying Phe209 and Cys207 with little vertical differences, while 
Asp208 occupy very different spots on the vertical plane, (c) horizontal view of active site with search 
model 3SLS and apo-MEK1 structure overlaid showing Phe209 and Cys207 with minimal differences, 
while the apo-MEK1 structure’s Asp208 is flipped away from the search model’s Asp208 position. 
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Figure 6. MEK1 45 – 393 w/ SVQSDI linker with Cu2+ bound in the active site: (a) labeled residues 
interacting and coordinating the Cu2+ atom, (b) the density cloud with a Cu2+ atom built in after refinement.  
The Cu2+ density cloud appears to be sharing space with C207, which could indicate a bond forming or 
simply a strong coordination residue, (c) the Cu2+’s drawn coordinating sites and distances to determine the 
coordination geometry of Cu2+ and the coordinating residues.  Given the distances and residue positions 
square planar was the determined Cu2+ coordination geometry. 
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Figure 7. Overlay of MEK1 45 – 393 w/ SVQSDI apo (pink) and Cu-bound (cyan) structures.  Distinct 
change of H188 flipping towards the active site to coordinate the Cu atom.  Asp208 side chain and 
backbone both move back to coordinate the Cu atom as well.  The Cys207 side chain moves closer to the 
Cu atom, which correlates to the shared density observed when solving the structure (Figure 5b).  Phe209 
shifts outward to cap the Cu atom, which potentially helps strengthen the other coordinating interactions. 
 
In vitro Studies of Copper Regulation of MEK1 
To functionally characterize the importance of the Cu ligands observed in the 
crystal structure, mutagenesis studies targeted the H188 and C207 residues.  While D208 
does coordinate the Cu ion, it is also a part of the DFG-motif, which is responsible for 
contributing to kinase activity within the active site.  Therefore, it was decided to not 
mutate D208 since it would be difficult to distinguish between effects on catalysis from 
Cu interaction.  New constructs harboring mutated residues were prepared including: 
C207S, H188A, and a H188A/C207S double mutant.  The wild-type and mutant 
constructs were qualitatively tested for activity using the western immunoblotting 
technique.  The blot results clearly indicated a change in the kinase activity. Compared to 
wild type MEK1, MEK1- C207S showed reduced ERK2 phosphorylation while MEK1-
H188A has no detectable activity (Figure 8).  As mentioned previously, H188 is a part of 
the MEK1 HRD-motif.  Depending on the kinase, the HRD-His or HRD-Asp residues are 
important because they mediate H-bonds to the Asp residue within the DFG-loop of the 
kinase, which mediates kinase activation.14  The mechanistic importance of the HRD-His  
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Figure 8. Initial Western blots of MEK1 Full Length (FL) wild type (wt), H188A, and C207S GST-tagged 
constructs.  These were conducted show active protein was being produced during protein purification and 
could be used for additional kinase activity measurement assays. 
 
position has not been studied, thus it is unknown how the HRD-His would affect kinase 
activity.  Its mutation in other studies either causes a reduction (~30%) or elimination of 
activity dependent on the kinase studied.13  
We then carried out a more quantitative enzyme-linked immunosorbent assay 
(ELISA), to assess MEK1 activity.  The initial activity counts of p-ERK signal during the 
optimization of the ELISA was quite low, making it difficult to determine the effect of 
mutations on MEK1 activity.  To overcome this, additional mutations were made in 
MEK1 at residues to mimic the phosphorylated active form of MEK1, S218D and S222D 
(MEK1-DD).  We found that MEK1-DD was 46 times more active than MEK1-WT 
(Appendix 1).  This phosphomimetic construct, MEK-DD, was utilized during the ELISA 
assay to reduce protein usage and increase activity counts to better observe changes 
caused by the mutations and Cu-addition.  After testing various concentrations of Cu, 
inhibition was observed (Figure 9) instead of the activation observed in previous studies.3  
Slow incorporation of Cu through overnight dialysis was attempted, since this would 
allow the Cu to be added gradually to MEK1 and prevent the protein from crashing out of 
solution.  Each of these was tested on a Western blot and ELISA for activity; however, no 
signal was detected.  ELISA experiments were further conducted on MEK1-DD, MEK1-
WT, and mutant constructs in the presence and absence of Cu.  This lead to the 
conclusion that all solutions used killed the kinase during dialysis (Figure 10).  Testing 
other variables, such as kinase buffers (Figure 11a), protein concentrations, and other 
metals, inhibition was the primary observation.  When testing different reducing agents 
(Figure 11b) without additional additives, activation at various levels was observed.  
Even with the C207S mutant that has drastically reduced activity compared to wild type, 
inhibition was still consistently observed (Figure 12). 
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Figure 9. Varying Cu concentrations with 200 nM MEK1-6His cut FL wt and 4.5 µM ERK-GST K54R.  
This graph shows the activity counts (y-axis) with standard errors and a negative correlation, signaling 
inhibition. 
 
To address the possibility that during growth or purification of MEK1, 
endogenously bound metals were binding to MEK1, and thus preventing Cu binding, the 
metal  chelator ammonium tetrathiomolybdate (TTM) was added to a dialysis of MEK1 
before the sizing column buffer change.  This TTM-purified MEK1-WT and MEK1-DD 
was used in the ELISA assay with 1 mM DTT and varied Cu2+ concentrations from 39 
nM – 10 μM.  The ELISA data revealed that MEK1 wt and MEK1 DD are consistently 
inhibited by Cu even after purification with TTM (Figure 13 a,b).  Finally, reducing agent 
dithiothreitol (DTT) was added to the kinase buffer to better simulate a cell’s reducing 
environment.  This would not only provide a better environment for the kinase, but effect 
any important elemental oxidation states. This was further investigated by keeping the 
DTT or Cu levels constant and varying Cu or DTT concentrations, respectively.  We 
observed that adding DTT alone or in excess of Cu did show significant MEK1 
activation, but the addition of Cu to DTT typically showed dose response MEK1 
inhibition (Figure 14). This data collectively indicates that DTT activates bacterially 
produced recombinant homogeneously purified MEK1 while Cu reduces MEK1 activity, 
consistent with what is expected from the observed Cu binding site in the crystal 
structure. 
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Figure 10. Various dialysis solutions used with 25 nM MEK1-6His cut FL DD and 200 nM MEK1-6His 
cut FL wt w/ TTM to slowly add Cu to the system.  The solutions consist of the following: (a) 100 mM 
NaCl, 20 mM Tris pH 7.5, (b) 0 nM Cu2+, 25 nM MEK1 DD wt, (c) 50 nM Cu2+, 25 nM MEK1 DD wt, (d) 
1 µM Cu2+, 25 nM MEK1 DD wt, (e) 50 nM Cu2+, 50 nM Imidazole, 25 nM MEK1 DD wt, (f) 1 µM Cu2+, 
1 µM Imidazole, 25 nM MEK1 DD wt, (g) 1 µM Cu2+, 1 µM Imidazole, 200 nM MEK1 wt, (h) 1 µM Cu2+, 
1 µM Imidazole, 200 nM MEK1 wt w/ TTM, 2 µM Cu2+, (i) 1 µM Imidazole, 25 nM MEK1 DD wt.  The 
red line signals the baseline activity of MEK1 in the kinase buffer.  All of the others were overnight 
dialysis with Cu, and are well below the red line, signaling that all of the MEK1 kinase in those solutions 
showed no activity.  The one solution (g) with activity above the baseline was re-run and was dead upon re-
testing. 
 
Cu/Ag Displays Activation of Crudely Purified Recombinant MEK1 
To better understand the DTT and Cu interaction, Western blots were revisited in 
order to use smaller amounts of protein and test more protein–additive reactions.  Both 
MEK1-WT with either a 6His or GST tag, displayed inhibition with Cu2+ without DTT 
and baseline activity was surpassed upon DTT addition (Figure 15).  While both GST and 
His constructs showed inhibition without DTT and no change with DTT present, there 
were differences observed with activity levels between the same constructs differing 
solely in their solubility tags.  The MEK-GST tagged proteins tended to show stronger 
bands in lane 2 & 9, signaling more activity than the MEK1-His proteins in lane 5 & 12.  
Since endogenously bound metal is a possibility with a 6His-tag through either culture 
growth with media or interaction with Ni2+ on the resin, it was expected that metal was 
binding to the Cu-binding site through purification and introducing artifacts to the study.  
For these reasons, the GST-tagged constructs were used for further studies.   
 Oxidation state became a factor to consider, since DTT is required for activation 
and appears to be interacting and reducing the kinase or Cu2+ to allow for activation.  For 
this reason, Cu+ and Ag+ were analyzed alongside with Cu2+.  Since Cu+ is extremely 
unstable and unfavorable, Tetrakis(acetonitrile) copper(I) hexafluorophosphate, 
abbreviated to Cu(I) for this study, was used to add Cu+ to the solution.  Cu(I) is a  
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Figure 11. Other variables tested to characterize the Cu interaction with MEK1: (a) 25 nM MEK-6His cut 
FL DD undergoing dialysis with buffers varying reducing agents, imidazole concentrations, and Cu 
concentrations, where all dialysis solutions rendered the MEK1 kinase dead and (b) 25 nM MEK-6His cut 
FL DD with different reducing agents at the same concentration (50 μM) to see their effects on the kinase.  
All of the ones tested activated MEK1 to various degrees. 
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Figure 12. Testing C207S mutant with increasing Cu concentrations. 25 nM MEK-6His cut FL DD C207S 
to test increasing Cu concentrations’ effects on a mutant construct, where Cu also killed the C207S’s 
minimal activity levels with a constant 1 mM DTT present. 
 
compound that stabilizes the Cu+ atom through multiple N-cyanide bonds and the PF6
- 
allowing additional stabilization of the Cu+ compound.   
MEK1 FL wt 6His-cut was tested first, due to its high purity and consistent 
purification results (Appendix 2).  When run with Cu2+, Cu(I), and Ag+, Westerns 
displayed consistent inhibition at the few concentrations tested.  In order to further probe 
the possibility of activation at a low concentration, serial dilutions for Cu(I) (Figure 16a) 
and Ag (Figure 16b) were conducted.  The Cu(I) Western blot displayed correlated 
inhibition whereas the metal concentration increases, the activity level decreases without 
DTT in lanes 2-7 (Figure 16a).  The Ag Western blot displayed possible activation 
without DTT present in lanes 4-6 that seem to have larger p-ERK bands than MEK1 wt 
without additives in lane 2 (Figure 16b).  Additionally, there are some instances with 
DTT where Ag appear to inhibit in lanes 12-13 where the bands are smaller than the 
MEK1 wt without additives in lane 10 (Figure 16b). 
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Figure 13. MEK1 purified w/ TTM and varying Cu concentrations:  (a) 200 nM MEK-6His cut FL wt w/ 
TTM and DTT, showing inhibition as the Cu concentrations increase, specifically where the Cu:DTT 
concentration ratio is 1.25:1 or higher, (b) 25 nM MEK-6His cut FL DD with DTT and Cu which sees 
baseline activity, while Cu additions without DTT kill MEK1’s activity. 
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Figure 14. Varying Cu and DTT concentration ratios with 25 nM MEK-6His cut FL DD. The bottom 
values on the x-axis are the DTT concentrations present in that set of samples.  Each color represents a 
different Cu concentration.  There is a Cu:DTT concentration ratio that must occur in order for MEK1 to 
remain active and counteract the inhibitory effects of Cu. 
 
 
 
Figure 15. MEK1-wt purified with 6His- or GST-tag.  The following species were present (+) or absent (-): 
(a) 4.5 µM ERK-GST K54R, (b) 200 nM MEK-GST FL wt, (c) 200 nM MEK-His cut FL wt, (d) 5 µM 
CuSO4, (e) 10 µM CuSO4, and (f) 2 mM DTT.  Lanes 2-7 have an absence of DTT and show inhibition at 
two Cu concentrations, while lanes 9-14 have 2 mM DTT present and have the same activity levels as the 
samples with no Cu added.  The Coomassie stained PVDF membrane blot below shows even loading 
amongst the lanes and confirms that the results are true. 
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Figure 16. MEK1 FL wt 6His-cut metal analysis by Western blot of: (a) Cu(I) with a: 200 µg/ µL ERK-
GST K54R, b: 200 nM MEK-6His cut FL wt, c: Cu(I), d: 2 mM DTT and (b) Ag with a: 200 µg/ µL ERK-
GST K54R, b: 200 nM MEK-6His cut FL wt, c: Ag, d: 2 mM DTT.  Inhibition is the clear trend for Cu(I), 
while Ag shows some possible activation without DTT present. Both have the Coomassie stained PVDF 
membrane blot below displaying even loading amongst the lanes and confirms that the results observed. 
 
MEK1-GST FL wt was then prepared and concentrated after the dialysis step of 
purification.  Some GST protein purifications do not include an S200 sizing run after 
eluting off of an affinity column due to their high specificity.  The crude (unsized) 
MEK1-GST FL wt was determined by a gel electrophoresis (Figure 17a).  Although the 
sample was clearly not pure, it was analyzed for MEK1 activity and Cu activation, due to 
this purification mimicking what was conducted by Brady et al. to demonstrate Cu 
activation.3 
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Figure 17. MEK1 FL wt GST crude sample analysis: (a) gel electrophoresis of MEK1 FL wt GST without 
S200 run and (b) Western blot of MEK1 FL wt GST crude concentrated sample with the following species 
present or absent.  The Coomassie stained PVDF membrane blot below shows even loading amongst the 
lanes and confirms that the results are true. 
 
The Western blot analysis demonstrated that the crudely purified MEK-GST FL 
wt was activated upon the addition of Cu2+, Cu+, and Ag+ without DTT present, while 
activity levels equal to MEK1 with no metal additives was achieved when DTT was 
present (Figure 17b).  In order to identify what was causing the activation, a new GST-
MEK1-WT sample was prepared and fractions from the glutathione resin were analyzed 
for kinase activity and metal activation using Western blot.  This Western blot displayed 
four fractions with activity, each with its own interaction profile to the additives. Fraction 
#14 showed the strongest p-ERK signal, with Cu2+ activation without DTT present and 
Ag+ activation and Cu2+ inhibition with DTT present (Figure 18). 
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Figure 18. Western dot blot of MEK1 FL wt GST fractionated samples. 
 
Fraction #14 was re-fractionated on an S200 sizing run and displayed strong 
lower bands (~40 kDa) that did not correlate to the MEK1-GST FL wt expected 
molecular weight band (72 kDa) (Figure 19a).  The first three fractions of this gel 
displayed bands around 72 kDa and were combined and run on another Western (Figure 
19b), which confirmed the dot blot results of activation apparent for Cu2+ and Cu+ 
without DTT present and slight activation with Ag+ with DTT present.   
From these results, a gel with Fraction #14 was run and the strong lower bands, 
Band A and B (Figure 20) were sent for gel mass spectrometry to determine what is 
potentially causing the activation observed in crude MEK1-GST FL wt samples and 
reactions.  These bands while more prominent within specific fractions, are present in all 
of the fractions and for this reason could be contributing to the observed activity levels 
regardless of its concentration within the specific fraction.  Even at low concentrations, 
the degradation product’s effect could be so strong that it is able to overcome the full 
length and other degradation product interactions occurring.  The intact band was 
determined to be MEK1 –GST FL with no modifications and that Bands A and B 
contained mostly MEK1 proteins with few contaminants.  Band was determined to be 
mostly comprised of N-terminus to K402 and Band B was composed of N-terminus to 
K330.  The GST sequence that is part of this construct runs from residues 1-250, thus 
these residues had to be subtracted to determine exactly which residues of MEK1 were 
within the degradation bands.  After the subtraction, Band A was comprised of MEK1 
residues 1-152 and Band B was comprised of MEK1 residues 1-80.   
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Figure 19. MEK1 FL wt GST Fraction #14 analysis: (a) gel electrophoresis of S200 run of Fraction #14 
where the upper bands (around MEK1 FL wt GST’s kDa) are only present in fractions 12-14 and (b) 
Western blot of Fraction #14’s combined and concentrated sample, which was consistent with the initial 
Western dot blot results for Fraction #14 (Figure 17), activation observed with Cu2+ and Cu(I) without DTT 
and Ag+ with DTT. 
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Figure 20. The mass spectrometry gel after destaining for 2 hours in destain solution.  The bands were 
selected (A and B) to compare with the full length (intact) protein.  A gel control was taken to subtract from 
background signal caused by the acrylamide gel. 
 
 Since both of these degradation bands did not include any of the observed sites 
C207, H188, and D208’s backbone from the crystal structure and these sites were far 
upstream from the last residue, 152, within the degradation band.  Another interaction site 
must be present.  After returning to the MEK1 Cu-bound structure and scanning MEK1’s 
residues 45-152, another Cu-anomalous signal was observed at the C121 site (Figure 
21a).  This was not thought to be a true interaction within the structure, since this 
anomalous density was only present in one subunit; however, upon overlaying both 
subunits within the asymmetric subunit, the C121 and K185 side chains did line up.  This 
led to the conclusion that while the anomalous density was not present in the other 
subunit, the presence of Cu was biologically relevant.  This biological relevancy comes 
from the side chains being in the same conformation for both subunits within the 
asymmetric unit.  This was further confirmed by overlaying the apo- and Cu-bound 
structures, where drastic conformational changes occur for H184 and K185 with C121 
remaining in the same position (Figure 21b). 
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Figure 21. Analysis of the C121 site: (a) the Cu-anomalous signal map showing an interaction occurring at 
the C121 site, which is similar to the C207 site’s anomalous signal density, and interacting with the K185 
and (b) overlay comparison between apo-(pink) and Cu-bound(cyan) MEK1 structures at the C121 site. 
 
Furthermore, the K185 and H184 are only a few residues downstream from the 
H188 position, which is involved in coordinating copper near the kinase’s active site.  
Given that these two sites are in close proximity, it is possible that one is a regulatory 
site, while the other affects activity depending on the presence or absence of copper at the 
other site.  The flipping of H188 would affect the residues on that same strand, ie. K185 
and H184.  Since the H188 is part of the regulatory HRD motif, it is likely that this 
histidine is aiding in chelating the copper near the active site, similar to its effect when 
magnesium (Mg2+) is present for ATP hydrolysis.  The C121 site’s copper interaction 
could then be rotating as a subsequent action of the H188 flipping inward toward its Cu 
coordination site causing the change in kinase activity.  These two Cu sites in 
combination with the oxidation state of the Cu present could be the key factors affecting 
the kinase activity of MEK1.   
 
Summary and Conclusions 
The X-ray structures reveal that MEK1 as in an inactive kinase conformation with 
the DFG-Phe flipped in and the square planar conformation of the Cu ion leads to the 
conclusion that the metal is in the Cu2+ oxidation state.  In vitro studies using bacterially 
expressed homogeneously purified MEK1 is inhibited by Cu and Ag, while crudely 
purified MEK1 is activated by these metals. The requirement of reducing agent suggests 
that either the kinase (MEK1) or the metal (Cu) need to be or are being reduced in order 
for the activation to occur.  From these data, the current model appears to be that a MEK1 
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interacting factor (a piece of MEK1 or another protein) mediates the Cu activation 
through a different site than the inhibitory site observed in the crystals.  Thus the two Cu 
interaction sites, C207 and C121, have different effects on MEK1’s activity.  For the 
highly purified recombinant MEK1, it is plausible that there is a certain threshold 
concentration for Cu2+, where its concentration causes a switch from activation and 
inhibitory.  The number of Cu atoms binding and the oxidation state of the metal appear 
to be key components to the effect metal binding on MEK1 activity.  Given that MEK1 is 
a kinase within an extremely efficient kinase cascade pathway, activity can increase to 
unsafe levels rather quickly if unregulated.  This could be a potential feedback loop for 
inhibition of high levels of MEK1 activity.   
 
Future Directions 
This study has been able to address some questions about the mechanism for how 
copper interacts and affects MEK1, but has also resulted in new questions about how 
MEK1 could interact with other metals such as Ag to mediate both kinase activation and 
inhibition.  The Cu interaction characterization, including both the C207 and C121 sites, 
should be completed with an EPR or XAS assay, which can detect the minute changes 
that occur from the binding event when a single element (Cu) binds to MEK1.  While the 
Cu binding events greatly affect activity, they are not large binding events, like ATP 
binding to the active site, thus its small binding event is hard to detect unless using 
hypersensitive techniques.  It would be helpful to further confirm the oxidation state of 
Cu when bound/interacting with MEK1, to perhaps tease out the differences between Cu+ 
and Cu2+ binding to MEK1, although Cu+ binding should be mimicked with Ag+ which is 
technically easier to produce in homogeneous form.  Findings in the Ag+ interactions in 
this study hints that further studies should be pursued to determine the activation capacity 
of Ag+ compared to Cu.  Metals binding to the active site can be a way to probe this 
location through conformational changes and allow for certain inhibitors to bind stronger 
and in specific ways.  By better understanding how metal binding affects MEK1 activity, 
new inhibitors may be designed for MEK1.   
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Appendices 
 
Appendix 1. Enzyme-Linked ImmunoSorbent Assay, Comparison of activity counts between (a) 
MEK1 FL wt and (b) MEK1 FL DD at various concentrations.  As the concentration positively 
increases so do the activity levels for both untagged constructs.  The difference occurs when 
phosphomimetic MEK1 construct (MEK1 FL DD) is tested and has higher activity counts (~45x) 
at all concentrations.  
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Appendix 2. Acrylamide Gel Electrophoresis, Comparison of a MEK-6His cut FL wt purification 
and MEK-GST FL wt purification.  Both of these gels are after the final Superdex S200 sizing 
run.  (a) MEK-6His cut FL wt has a singular clean set of bands at the correct molecular weight 
(44 kDa).  (b) MEK-GST FL wt has the top band of FL intact MEK-GST (72 kDa) with multiple 
lower bands.  These lower bands are degradation products caused by the GST tag.  The 
degradation products are various pieces of the MEK-GST FL wt at the various lower molecular 
weights. 
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